Portada›Martes 18 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, martes 18 de noviembre de 2025

Los 34 documentos que 28 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← lunes 17 de noviembre de 2025 · miércoles 19 de noviembre de 2025 →

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. CVKDCadrenal Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-277835 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated March 20, 2024) Up to $3,438,062 Shares of Common Stock We have entered into an At the Market Offering Agreement, dated March 11, 2024 (the “sales agreement”), with H.C. Wainwright & Co., LLC (“Wainwright” or the “sales agent”) relating to the sale of shares of our common stock, par value $0.001 per share…
2. FENCFENNEC PHARMACEUTICALS INC.424B5Nueva emisión de acciones con precioEDGAR
3. KTTAPasithea Therapeutics Corp.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …development and commercialization activities. 6 The report of our independent registered public accounting firms for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Due to the uncertainty of our ability to meet our current operating and capital expenses, in its report on our audited annual financial statements as of and for the year ended December 31, 2024, our…
4. OLMAOlema Pharmaceuticals, Inc.424B5Nueva emisión de acciones con precioEDGAR
5. SHPHShuttle Pharmaceuticals Holdings, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …incorporated herein in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars, LLP contains an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern. 9 INFORMATION INCORPORATED BY REFERENCE The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you…
6. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
7. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR
8. KZIAKAZIA THERAPEUTICS LTD424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

1. DSGNDesign Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
2. NEUPNeuphoria Therapeutics Inc.SC 13D/ACambio en participación significativaEDGAR
3. PMCBPharmaCyte Biotech, Inc.SC 13D/ACambio en participación significativaEDGAR
4. TRDAEntrada Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. ARWRARROWHEAD PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
   En el documentoEl ensayo alcanzó su objetivo principaltexto original ▸

   …was supported by clinical data from the Phase 3 PALISADE study, a randomized, double-blind, placebo-controlled trial in adults with clinically diagnosed or genetically confirmed FCS. The PALISADE study met its primary endpoint and all multiplicity-controlled key secondary endpoints, including demonstrating significant reductions in triglycerides and APOC3. In PALISADE, 25 mg REDEMPLO achieved deep and durable reductions in…

   En el documentoDesignación de medicamento huérfanotexto original ▸

   …patients at each stage of the treatment journey with REDEMPLO, including financial assistance options for eligible patients. REDEMPLO will be available in the U.S. before the end of the year. REDEMPLO was granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the FDA for the treatment of patients with FCS and was granted Orphan Medicinal Product Designation by the European Medicines Agency for the treatment of patients with FCS. Webcast and Conference Call…

   En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸

   …patients at each stage of the treatment journey with REDEMPLO, including financial assistance options for eligible patients. REDEMPLO will be available in the U.S. before the end of the year. REDEMPLO was granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the FDA for the treatment of patients with FCS and was granted Orphan Medicinal Product Designation by the European Medicines Agency for the treatment…

   En el documentoDesignación de vía rápida (Fast Track)texto original ▸

   …patients at each stage of the treatment journey with REDEMPLO, including financial assistance options for eligible patients. REDEMPLO will be available in the U.S. before the end of the year. REDEMPLO was granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the FDA for the treatment of patients with FCS and was granted Orphan Medicinal Product Designation by the European Medicines Agency for the treatment of patients with…
2. DRMADermata Therapeutics, Inc.8-KFin de acuerdo materialEDGAR
3. ETONEton Pharmaceuticals, Inc.8-K/ACompra o venta de activos completadaEDGAR
4. HROWHARROW, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
5. SNGXSOLIGENIX, INC.8-KAviso de incumplimiento de cotizaciónEDGAR
6. ALZNAlzamend Neuro, Inc.8-KOtros hechos relevantesEDGAR
7. COGTCogent Biosciences, Inc.8-KNuevo acuerdo materialEDGAR
8. CVKDCadrenal Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
9. CYPHCYPHERPUNK TECHNOLOGIES INC.8-KOtros hechos relevantesEDGAR
10. FENCFENNEC PHARMACEUTICALS INC.8-KNuevo acuerdo materialEDGAR
11. GNPXGenprex, Inc.8-KOtros hechos relevantesEDGAR
12. HURATuHURA Biosciences, Inc./NV8-KOtros hechos relevantesEDGAR
13. INMBInmune Bio, Inc.8-KCambio en el consejo o la direcciónEDGAR
14. INSMINSMED Inc8-KOtros hechos relevantesEDGAR
15. LITSLite Strategy, Inc.8-KCambio en el consejo o la direcciónEDGAR
16. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
17. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
18. OLMAOlema Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
19. RMTIROCKWELL MEDICAL, INC.8-KCambio en el consejo o la direcciónEDGAR
20. TNXPTonix Pharmaceuticals Holding Corp.8-KOtros hechos relevantesEDGAR
21. VBIOValion Bio, Inc.8-KOtros hechos relevantesEDGAR
22. ZYMEZymeworks Inc.8-KCambio en el consejo o la direcciónEDGAR

← lunes 17 de noviembre de 2025 · miércoles 19 de noviembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.